8-year SAVR outcomes of RESILIA tissue valves 1
(Echo-derived mean gradient, mmHg)
MITRIS RESILIA Mitral Valve
What sets the MITRIS RESILIA valve apart? Data.
Since 2004, RESILIA tissue has been extensively studied. The growing body of clinical evidence supports RESILIA tissue valves' hemodynamic performance and resistance to structural valve deterioration in the mitral position.1,2
Clinically stable hemodynamics 1,2
COMMENCE mitral trial
(Echo-derived median gradient, mmHg)
COMMENCE mitral trial2
Clinically stable hemodynamics and one incident of structural valve deterioration (SVD) through 5 years.
98.7%
freedom from SVD
97.1%
freedom from reoperation
Juvenile sheep study — mitral position3
Reduced calcification after 8 months, exceeding the 5-month reporting requirement
72%
reduction in calcification
RESILIA tissue valve
Control valve (6900P)
Ongoing real-world clinical outcomes study4
This global study is planned to enroll up to 500 patients implanted with the MITRIS RESILIA valve
RESILIA tissue data
Learn more about the promising results and conclusions of the various RESILIA tissue studies
MITRIS RESILIA valve specifications
See the valve dimensions, sizing, accessories, and resources.
References
- Kaneko, T, Johnston D, Bavaria JE, et al. Propensity-matched 8-year Outcomes Following Surgical Aortic Valve Replacement With Novel Calcificationresistant Versus Contemporary Tissue Bioprostheses. Presented at the Heart Valve Society Annual Scientific Meeting, April 2025.
- Heimansohn DA, Baker C, Rodriguez E, et al. Mid-term outcomes of the COMMENCE trial investigating mitral valve replacement using a bioprosthesis with a novel tissue. JTCVS Open. 2023;15:151-163.
- Flameng W, Hermans H, Verbeken E, et al. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. J Thorac Cardiovasc Surg. 2015;149(1):340-345
- Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve (MOMENTIS). https://clinicaltrials.gov/study/NCT05526560
Important safety information
Important safety information
MITRIS RESILIA Mitral Valve
Indications: For use in replacement of native or prosthetic mitral heart valves.
Contraindications: There are no known contraindications with the use of the MITRIS RESILIA mitral valve.
Complications and Side Effects: Thromboembolism, valve thrombosis, hemorrhage, hemolysis, regurgitation, endocarditis, structural valve deterioration, nonstructural dysfunction, stenosis, arrhythmia, transient ischemic attack/stroke, congestive heart failure, myocardial infarction, ventricular perforation by stent posts, any of which could lead to reoperation, explantation, permanent disability, and death.
CAUTION: US law restricts this device to sale by or on the order of a physician. See Instructions for Use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events.